How to Buy biofilchem Shares on Fincept?
You can buy Biofil Chemicals and Pharmaceuticals Limited shares on Different Brokers & Banks by creating an account and completing KYC verification online.
NSE: Biofil Chemicals and Pharmaceuticals Limited Share Price Today, Share Analysis, Latest Updates & Insights | Fincept
Stay informed with the latest announcements for Biofilchem, including updates on board meetings and corporate actions.
Biofil Chemicals and Pharmaceuticals Limited - https://www.biofilgroup.net
Biofil Chemicals and Pharmaceuticals Limited manufactures and trades in pharmaceuticals in India. It operates through Pharmaceutical and Chemical divisions. The company offers basic drugs and chemicals, such as sodium chloride, potassium chloride, sodium citrate, diethyl carbamazine citrate, ferrous sulphate, dried ferrous sulphate, ferrous fumerate, micro crystalline cellulose, and dicyclomine hydrochloride; and plastic drippers and caps for packing applications. It also provides job work service for manufacturing pharmaceutical drugs. Biofil Chemicals and Pharmaceuticals Limited was incorporated in 1985 and is based in Indore, India.
Biofil Chemicals and Pharmaceuticals Limited Share Price Today
51.99
OPEN
53.48
HIGH
51.51
LOW
52.81
CLOSE
12 K
VOLUME
98 Cr
Market Cap
61132
Average Volume
Healthcare
Sector
NSI
Exchange
Biofil Chemicals and Pharmaceuticals Limited Share Analysis & 2025 Insights
Investor Presentations
| Date | Description | Download |
|---|
SIP
Lumpsum
Invested Amount: ₹
Estimated Returns: ₹
Total Value: ₹
NSE: BIOFILCHEM Stock Actions
Company |
Symbol |
ISIN |
Subject |
Ex Date |
Face Value |
Broadcast Date |
|---|---|---|---|---|---|---|
Biofil Chemicals & Pharmaceuticals Limited |
BIOFILCHEM |
INE829A01014 |
Annual General Meeting |
23 Sep 2024 |
10 |
N/A |
Biofil Chemicals & Pharmaceuticals Limited |
BIOFILCHEM |
INE829A01014 |
Annual General Meeting |
20 Sep 2023 |
10 |
N/A |
Biofil Chemicals & Pharmaceuticals Limited |
BIOFILCHEM |
INE829A01014 |
Annual General Meeting |
21 Sep 2022 |
10 |
N/A |
Biofil Chemicals & Pharmaceuticals Limited |
BIOFILCHEM |
INE829A01014 |
Annual General Meeting |
17 Sep 2021 |
10 |
N/A |
Biofil Chemicals & Pharmaceuticals Limited |
BIOFILCHEM |
INE829A01014 |
Annual General Meeting |
21 Sep 2020 |
10 |
N/A |
NSE: BIOFILCHEM Recent Announcements
Symbol |
Date |
Description |
Industry |
|---|---|---|---|
BIOFILCHEM |
30 Dec 2024, 17:31:47 |
Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent |
- |
BIOFILCHEM |
30 Dec 2024, 17:30:57 |
Appointment |
- |
BIOFILCHEM |
23 Dec 2024, 15:44:10 |
Trading Window-XBRL |
- |
BIOFILCHEM |
23 Dec 2024, 15:42:16 |
Trading Window |
- |
BIOFILCHEM |
16 Dec 2024, 19:40:22 |
Resignation |
- |
NSE: BIOFILCHEM Corporate Governance
Name |
Symbol |
Timestamp |
Submission Date |
XBRL Document |
|---|---|---|---|---|
Biofil Chemicals & Pharmaceuticals Limited |
BIOFILCHEM |
19 Oct 2024, 22:03:00 |
19 Oct 2024, 22:03:00 |
|
Biofil Chemicals & Pharmaceuticals Limited |
BIOFILCHEM |
19 Jul 2024, 18:08:00 |
19 Jul 2024, 18:08:00 |
|
Biofil Chemicals & Pharmaceuticals Limited |
BIOFILCHEM |
20 Apr 2024, 18:06:00 |
20 Apr 2024, 18:30:00 |
|
Biofil Chemicals & Pharmaceuticals Limited |
BIOFILCHEM |
20 Jan 2024, 12:45:00 |
20 Jan 2024, 13:15:00 |
|
Biofil Chemicals & Pharmaceuticals Limited |
BIOFILCHEM |
20 Oct 2023, 13:00:00 |
20 Oct 2023, 13:30:00 |
NSE: BIOFILCHEM Detailed Governance
Category |
Date of Birth |
Date of Initial Appointment |
DIN |
Director Name |
Status |
|---|---|---|---|---|---|
Chairperson Related To Promoters,Executive Director-MD |
17 Oct 1936 |
04 Jan 1985 |
00028819 |
RAMESH SHAH |
Active |
Non-Executive Director |
07 Apr 1985 |
30 Jul 2005 |
00326110 |
ROMIL SHAH |
Active |
Executive Director |
21 Jul 1961 |
25 Aug 2020 |
08818212 |
KETAN SHAH |
Active |
Independent Director |
27 Sep 1952 |
25 Aug 2020 |
08818263 |
ASHOK KUMAR RAMAWAT |
Active |
Independent Director |
24 Dec 1969 |
30 Jun 2021 |
09220291 |
SATISH BEOHAR |
Active |
NSE: BIOFILCHEM Board Meetings
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
|---|---|---|---|---|---|
Board Meeting Intimation |
BIOFILCHEM |
N/A |
INE829A01014 |
Biofil Chemicals & Pharmaceuticals Limited |
07 Nov 2024, 18:22:24 |
Financial Results |
BIOFILCHEM |
N/A |
INE829A01014 |
Biofil Chemicals & Pharmaceuticals Limited |
08 Aug 2024, 17:50:04 |
BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 30-May-2024 to consider and approve the Yearly Audited Financial results of the Company for the period ended March 2024 and Other business. |
BIOFILCHEM |
N/A |
INE829A01014 |
Biofil Chemicals & Pharmaceuticals Limited |
22 May 2024, 18:10:51 |
Financial Results |
BIOFILCHEM |
N/A |
INE829A01014 |
Biofil Chemicals & Pharmaceuticals Limited |
30 Jan 2024, 17:24:03 |
Financial Results |
BIOFILCHEM |
N/A |
INE829A01014 |
Biofil Chemicals & Pharmaceuticals Limited |
01 Nov 2023, 16:58:02 |
NSE: BIOFILCHEM Event Calendar
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
Description |
|---|---|---|---|---|---|---|
Financial Results/Other business matters |
BIOFILCHEM |
- |
INE829A01014 |
Biofil Chemicals & Pharmaceuticals Limited |
07 Nov 2024, 00:00:00 |
To consider and approve the financial results for the period ended September 30, 2024 and other business matters |
Financial Results |
BIOFILCHEM |
- |
INE829A01014 |
Biofil Chemicals & Pharmaceuticals Limited |
08 Aug 2024, 00:00:00 |
To consider and approve the financial results for the period ended Jun 30, 2024 |
Financial Results |
BIOFILCHEM |
- |
INE829A01014 |
Biofil Chemicals & Pharmaceuticals Limited |
22 May 2024, 00:00:00 |
To consider and approve the financial results for the period ended March 31, 2024 |
Financial Results |
BIOFILCHEM |
- |
INE829A01014 |
Biofil Chemicals & Pharmaceuticals Limited |
30 Jan 2024, 00:00:00 |
To consider and approve un-audited Financial Results for the quarter as well as nine months ended on 31st December, 2023 along with Limited Review Report thereon and to consider any other routine matters with the permission of Chair. |
Financial Results |
BIOFILCHEM |
- |
INE829A01014 |
Biofil Chemicals & Pharmaceuticals Limited |
01 Nov 2023, 00:00:00 |
To consider and approve the financial results for the period ended September 30, 2023 |
NSE: BIOFILCHEM Balance Sheet Data In (Cr)
| date | period_type | Ordinary Shares Number | Share Issued | Net Debt | Total Debt | Tangible Book Value | Invested Capital | Working Capital | Net Tangible Assets | Common Stock Equity | Total Capitalization | Total Equity Gross Minority Interest | Stockholders Equity | Other Equity Interest | Fixed Assets Revaluation Reserve | Retained Earnings | Additional Paid In Capital | Capital Stock | Common Stock | Total Liabilities Net Minority Interest | Total Non Current Liabilities Net Minority Interest | Other Non Current Liabilities | Non Current Deferred Taxes Liabilities | Current Liabilities | Other Current Liabilities | Current Deferred Taxes Liabilities | Current Debt And Capital Lease Obligation | Current Debt | Current Provisions | Payables | Other Payable | Accounts Payable | Total Assets | Total Non Current Assets | Other Non Current Assets | Non Current Prepaid Assets | Net PPE | Accumulated Depreciation | Gross PPE | Construction In Progress | Other Properties | Machinery Furniture Equipment | Buildings And Improvements | Land And Improvements | Properties | Current Assets | Other Current Assets | Restricted Cash | Prepaid Assets | Inventory | Other Inventories | Finished Goods | Work In Process | Raw Materials | Other Receivables | Taxes Receivable | Accounts Receivable | Allowance For Doubtful Accounts Receivable | Gross Accounts Receivable | Cash Cash Equivalents And Short Term Investments | Other Short Term Investments | Cash And Cash Equivalents | Cash Equivalents | Cash Financial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30T00:00:00 | quarterly | 16,273,800.00 | 16,273,800.00 | 2,983,000.00 | 4,551,000.00 | 183,965,000.00 | 188,516,000.00 | 103,252,000.00 | 183,965,000.00 | 183,965,000.00 | 183,965,000.00 | 183,965,000.00 | 183,965,000.00 | 21,227,000.00 | 0.00 | 0.00 | 0.00 | 162,738,000.00 | 162,738,000.00 | 236,436,000.00 | 3,554,000.00 | 0.00 | 3,554,000.00 | 232,882,000.00 | 613,000.00 | 0.00 | 4,551,000.00 | 4,551,000.00 | 671,000.00 | 227,047,000.00 | 0.00 | 227,047,000.00 | 420,401,000.00 | 84,269,000.00 | 1,000.00 | 0.00 | 84,268,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 336,134,000.00 | 10,779,000.00 | 0.00 | 0.00 | 68,040,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 255,113,000.00 | 0.00 | 0.00 | 2,202,000.00 | 634,000.00 | 1,568,000.00 | 0.00 | 0.00 |
| 2024-03-31T00:00:00 | quarterly | 16,273,800.00 | 16,273,800.00 | 3,463,000.00 | 4,389,000.00 | 182,028,000.00 | 186,417,000.00 | 98,831,000.00 | 182,028,000.00 | 182,028,000.00 | 182,028,000.00 | 182,028,000.00 | 182,028,000.00 | 19,290,000.00 | 37,621,000.00 | -316,944,000.00 | 83,331,000.00 | 162,738,000.00 | 162,738,000.00 | 288,799,000.00 | 3,554,000.00 | 0.00 | 3,554,000.00 | 285,245,000.00 | 1,000.00 | 2,400,000.00 | 4,389,000.00 | 4,389,000.00 | 2,400,000.00 | 277,014,000.00 | 1,465,000.00 | 275,549,000.00 | 470,827,000.00 | 86,751,000.00 | -1,000.00 | 509,000.00 | 86,243,000.00 | -30,262,000.00 | 116,505,000.00 | 0.00 | 2,433,000.00 | 38,997,000.00 | 30,116,000.00 | 44,959,000.00 | 0.00 | 384,076,000.00 | 264,000.00 | 0.00 | 5,189,000.00 | 25,497,000.00 | -1,000.00 | 8,031,000.00 | 0.00 | 17,467,000.00 | 0.00 | 0.00 | 330,291,000.00 | -1,276,000.00 | 331,567,000.00 | 22,835,000.00 | 21,909,000.00 | 22,835,000.00 | 0.00 | 22,835,000.00 |
| 2024-03-31T00:00:00 | annual | 16,273,800.00 | 16,273,800.00 | 3,463,000.00 | 4,389,000.00 | 182,028,000.00 | 186,417,000.00 | 98,831,000.00 | 182,028,000.00 | 182,028,000.00 | 182,028,000.00 | 182,028,000.00 | 182,028,000.00 | 19,290,000.00 | 37,621,000.00 | -316,944,000.00 | 83,331,000.00 | 162,738,000.00 | 162,738,000.00 | 288,799,000.00 | 3,554,000.00 | 0.00 | 3,554,000.00 | 285,245,000.00 | 1,000.00 | 2,400,000.00 | 4,389,000.00 | 4,389,000.00 | 2,400,000.00 | 277,014,000.00 | 1,465,000.00 | 275,549,000.00 | 470,827,000.00 | 86,751,000.00 | -1,000.00 | 509,000.00 | 86,243,000.00 | -30,262,000.00 | 116,505,000.00 | 0.00 | 2,433,000.00 | 38,997,000.00 | 30,116,000.00 | 44,959,000.00 | 0.00 | 384,076,000.00 | 264,000.00 | 0.00 | 5,189,000.00 | 25,497,000.00 | -1,000.00 | 8,031,000.00 | 0.00 | 17,467,000.00 | 0.00 | 0.00 | 330,291,000.00 | -1,276,000.00 | 331,567,000.00 | 22,835,000.00 | 21,909,000.00 | 22,835,000.00 | 0.00 | 22,835,000.00 |
| 2023-09-30T00:00:00 | quarterly | 16,273,800.00 | 16,273,800.00 | 5,295,000.00 | 5,640,000.00 | 176,704,000.00 | 182,344,000.00 | 92,630,000.00 | 176,704,000.00 | 176,704,000.00 | 176,704,000.00 | 176,704,000.00 | 176,704,000.00 | 13,966,000.00 | 0.00 | 0.00 | 0.00 | 162,738,000.00 | 162,738,000.00 | 245,458,000.00 | 3,787,000.00 | 0.00 | 3,787,000.00 | 241,671,000.00 | 1,100,000.00 | 0.00 | 5,640,000.00 | 5,640,000.00 | 2,049,000.00 | 232,882,000.00 | 0.00 | 232,882,000.00 | 422,162,000.00 | 87,861,000.00 | 0.00 | 0.00 | 87,861,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 334,301,000.00 | 9,015,000.00 | 0.00 | 0.00 | 50,730,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 273,981,000.00 | 0.00 | 0.00 | 575,000.00 | 230,000.00 | 345,000.00 | 0.00 | 0.00 |
| 2023-03-31T00:00:00 | quarterly | 16,273,800.00 | 16,273,800.00 | 4,846,000.00 | 5,223,000.00 | 173,015,000.00 | 178,238,000.00 | 86,286,000.00 | 173,015,000.00 | 173,015,000.00 | 173,015,000.00 | 173,015,000.00 | 173,015,000.00 | 10,277,000.00 | 37,621,000.00 | -325,957,000.00 | 83,331,000.00 | 162,738,000.00 | 162,738,000.00 | 141,042,000.00 | 3,787,000.00 | 0.00 | 3,787,000.00 | 137,255,000.00 | -30,000.00 | 2,300,000.00 | 5,223,000.00 | 5,223,000.00 | 2,300,000.00 | 129,732,000.00 | 3,233,000.00 | 126,499,000.00 | 314,057,000.00 | 90,516,000.00 | -1,000.00 | 509,000.00 | 90,008,000.00 | -26,268,000.00 | 116,276,000.00 | 0.00 | 2,433,000.00 | 38,989,000.00 | 29,895,000.00 | 44,959,000.00 | 0.00 | 223,541,000.00 | 2,369,000.00 | 0.00 | 6,003,000.00 | 12,134,000.00 | -1,000.00 | 5,306,000.00 | 0.00 | 6,829,000.00 | 0.00 | 2,674,000.00 | 205,027,000.00 | -848,000.00 | 205,875,000.00 | 377,000.00 | 117,000.00 | 377,000.00 | 0.00 | 377,000.00 |
| 2023-03-31T00:00:00 | annual | 16,273,800.00 | 16,273,800.00 | 4,846,000.00 | 5,223,000.00 | 173,015,000.00 | 178,238,000.00 | 86,286,000.00 | 173,015,000.00 | 173,015,000.00 | 173,015,000.00 | 173,015,000.00 | 173,015,000.00 | 10,277,000.00 | 37,621,000.00 | -325,957,000.00 | 83,331,000.00 | 162,738,000.00 | 162,738,000.00 | 141,042,000.00 | 3,787,000.00 | 0.00 | 3,787,000.00 | 137,255,000.00 | -30,000.00 | 2,300,000.00 | 5,223,000.00 | 5,223,000.00 | 2,300,000.00 | 129,732,000.00 | 3,233,000.00 | 126,499,000.00 | 314,057,000.00 | 90,516,000.00 | -1,000.00 | 509,000.00 | 90,008,000.00 | -26,268,000.00 | 116,276,000.00 | 0.00 | 2,433,000.00 | 38,989,000.00 | 29,895,000.00 | 44,959,000.00 | 0.00 | 223,541,000.00 | 2,369,000.00 | 0.00 | 6,003,000.00 | 12,134,000.00 | -1,000.00 | 5,306,000.00 | 0.00 | 6,829,000.00 | 0.00 | 2,674,000.00 | 205,027,000.00 | -848,000.00 | 205,875,000.00 | 377,000.00 | 117,000.00 | 377,000.00 | 0.00 | 377,000.00 |
| 2022-03-31T00:00:00 | annual | 16,273,800.00 | 16,273,800.00 | 3,197,000.00 | 4,647,000.00 | 168,377,000.00 | 173,024,000.00 | 78,182,000.00 | 168,377,000.00 | 168,377,000.00 | 168,377,000.00 | 168,377,000.00 | 168,377,000.00 | 5,639,000.00 | 37,621,000.00 | -330,595,000.00 | 83,331,000.00 | 162,738,000.00 | 162,738,000.00 | 18,945,000.00 | 3,997,000.00 | -1,000.00 | 3,998,000.00 | 14,948,000.00 | -1,000.00 | 2,710,000.00 | 4,647,000.00 | 4,647,000.00 | 2,710,000.00 | 7,591,000.00 | 1,628,000.00 | 5,963,000.00 | 187,322,000.00 | 94,193,000.00 | -1,000.00 | 0.00 | 94,194,000.00 | -21,977,000.00 | 116,171,000.00 | 0.00 | 2,433,000.00 | 38,979,000.00 | 29,800,000.00 | 44,959,000.00 | 0.00 | 93,130,000.00 | 2,478,000.00 | 0.00 | 2,480,000.00 | 12,932,000.00 | 0.00 | 2,258,000.00 | 1,035,000.00 | 9,639,000.00 | 0.00 | 2,053,000.00 | 71,737,000.00 | -339,000.00 | 72,076,000.00 | 1,450,000.00 | 600,000.00 | 1,450,000.00 | 0.00 | 1,450,000.00 |
| 2021-03-31T00:00:00 | annual | 16,273,800.00 | 16,273,800.00 | 4,201,000.00 | 4,298,000.00 | 161,291,000.00 | 165,589,000.00 | 67,085,000.00 | 161,291,000.00 | 161,291,000.00 | 161,291,000.00 | 161,291,000.00 | 161,291,000.00 | -1,447,000.00 | 37,621,000.00 | -337,681,000.00 | 83,331,000.00 | 162,738,000.00 | 162,738,000.00 | 171,093,000.00 | 3,562,000.00 | 0.00 | 3,562,000.00 | 167,531,000.00 | 0.00 | 3,275,000.00 | 4,298,000.00 | 4,298,000.00 | 3,275,000.00 | 159,958,000.00 | 1,438,000.00 | 158,520,000.00 | 332,384,000.00 | 97,769,000.00 | 0.00 | 0.00 | 97,769,000.00 | -17,703,000.00 | 115,472,000.00 | 0.00 | 2,400,000.00 | 38,313,000.00 | 29,800,000.00 | 44,959,000.00 | 0.00 | 234,616,000.00 | 10,849,000.00 | 0.00 | 3,081,000.00 | 43,446,000.00 | 0.00 | 38,244,000.00 | 950,000.00 | 4,252,000.00 | 519,000.00 | 656,000.00 | 172,179,000.00 | 0.00 | 172,179,000.00 | 4,405,000.00 | 4,308,000.00 | 4,405,000.00 | 0.00 | 4,405,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1,000.00 | 0.00 | 0.00 | 0.00 | 478,000.00 | 1,684,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: BIOFILCHEM Cash Flow Data In (Cr)
| date | period_type | Free Cash Flow | Capital Expenditure | End Cash Position | Other Cash Adjustment Outside Changein Cash | Beginning Cash Position | Changes In Cash | Financing Cash Flow | Net Other Financing Charges | Interest Paid Cff | Net Issuance Payments Of Debt | Net Short Term Debt Issuance | Net Long Term Debt Issuance | Investing Cash Flow | Interest Received Cfi | Dividends Received Cfi | Net Investment Purchase And Sale | Net PPE Purchase And Sale | Sale Of PPE | Purchase Of PPE | Operating Cash Flow | Taxes Refund Paid | Change In Working Capital | Change In Other Current Liabilities | Change In Other Current Assets | Change In Payable | Change In Inventory | Change In Receivables | Other Non Cash Items | Provisionand Write Offof Assets | Depreciation And Amortization | Depreciation | Pension And Employee Benefit Expense | Net Income From Continuing Operations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | 23,708,000.00 | -229,000.00 | 22,835,000.00 | 0.00 | 376,000.00 | 22,459,000.00 | -1,249,000.00 | 82,566,000.00 | -415,000.00 | -83,400,000.00 | 0.00 | -83,400,000.00 | -229,000.00 | 0.00 | 0.00 | 0.00 | -229,000.00 | 0.00 | -229,000.00 | 23,937,000.00 | -1,561,000.00 | 10,515,000.00 | -459,000.00 | 551,000.00 | 149,050,000.00 | -13,363,000.00 | -125,264,000.00 | 415,000.00 | 0.00 | 3,994,000.00 | 3,994,000.00 | 1,921,000.00 | 8,653,000.00 |
| 2023-03-31T00:00:00 | annual | -1,224,000.00 | -106,000.00 | 376,000.00 | 0.00 | 1,449,000.00 | -1,073,000.00 | 151,000.00 | 0.00 | -425,000.00 | 576,000.00 | 576,000.00 | 576,000.00 | -106,000.00 | 0.00 | 0.00 | 0.00 | -106,000.00 | 0.00 | -106,000.00 | -1,118,000.00 | -2,326,000.00 | -10,473,000.00 | 984,000.00 | 500,000.00 | 120,536,000.00 | 797,000.00 | -133,290,000.00 | 425,000.00 | 0.00 | 4,291,000.00 | 4,291,000.00 | -966,000.00 | 7,930,000.00 |
| 2022-03-31T00:00:00 | annual | -2,898,000.00 | -699,000.00 | 1,449,000.00 | -1,000.00 | 4,405,000.00 | -2,956,000.00 | -58,000.00 | 0.00 | -406,000.00 | 348,000.00 | 348,000.00 | 348,000.00 | -699,000.00 | 0.00 | 0.00 | 0.00 | -699,000.00 | 0.00 | -699,000.00 | -2,199,000.00 | -3,165,000.00 | -13,966,000.00 | 61,000.00 | 7,574,000.00 | -152,557,000.00 | 30,514,000.00 | 100,442,000.00 | 406,000.00 | 0.00 | 4,376,000.00 | 4,376,000.00 | 101,000.00 | 10,149,000.00 |
| 2021-03-31T00:00:00 | annual | 5,442,000.00 | -5,667,000.00 | 4,405,000.00 | 0.00 | 2,560,000.00 | 1,845,000.00 | -8,303,000.00 | 0.00 | -681,000.00 | -7,622,000.00 | 0.00 | -7,622,000.00 | -961,000.00 | 0.00 | 0.00 | 0.00 | -961,000.00 | 4,706,000.00 | -5,667,000.00 | 11,109,000.00 | -6,776,000.00 | -6,150,000.00 | 4,555,000.00 | -8,432,000.00 | -100,656,000.00 | -26,524,000.00 | 124,907,000.00 | 681,000.00 | 0.00 | 4,119,000.00 | 4,119,000.00 | 46,000.00 | 19,189,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | -1,000.00 | 0.00 | 0.00 | 0.00 | 1,000.00 | 0.00 | 0.00 | -4,453,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: BIOFILCHEM Income Statement Data In (Cr)
| date | period_type | Tax Effect Of Unusual Items | Tax Rate For Calcs | Normalized EBITDA | Total Unusual Items | Total Unusual Items Excluding Goodwill | Net Income From Continuing Operation Net Minority Interest | Reconciled Depreciation | Reconciled Cost Of Revenue | EBITDA | EBIT | Net Interest Income | Interest Expense | Interest Income | Normalized Income | Net Income From Continuing And Discontinued Operation | Total Expenses | Diluted Average Shares | Basic Average Shares | Diluted EPS | Basic EPS | Diluted NI Availto Com Stockholders | Net Income Common Stockholders | Otherunder Preferred Stock Dividend | Net Income | Net Income Including Noncontrolling Interests | Net Income Extraordinary | Net Income Discontinuous Operations | Net Income Continuous Operations | Tax Provision | Pretax Income | Other Non Operating Income Expenses | Special Income Charges | Other Special Charges | Net Non Operating Interest Income Expense | Total Other Finance Cost | Interest Expense Non Operating | Interest Income Non Operating | Operating Income | Operating Expense | Other Operating Expenses | Depreciation And Amortization In Income Statement | Depreciation Income Statement | Selling General And Administration | Selling And Marketing Expense | General And Administrative Expense | Gross Profit | Cost Of Revenue | Total Revenue | Operating Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | 0.00 | 0.00 | 1.30 | 0.00 | 0.00 | 0.71 | 0.40 | 37.51 | 1.30 | 0.90 | -0.03 | 0.04 | 0.01 | 0.71 | 0.71 | 39.62 | 1.63 | 1.63 | 0.00 | 0.00 | 0.71 | 0.71 | 0.00 | 0.71 | 0.71 | 0.00 | 0.00 | 0.71 | 0.16 | 0.87 | 0.48 | 0.00 | 0.00 | -0.03 | 0.00 | 0.04 | 0.01 | 0.42 | 2.11 | 0.89 | 0.40 | 0.40 | 0.15 | 0.01 | 0.14 | 2.53 | 37.51 | 40.04 | 40.04 |
| 2023-03-31T00:00:00 | annual | 0.00 | 0.00 | 1.26 | 0.00 | 0.00 | 0.56 | 0.43 | 27.42 | 1.26 | 0.83 | -0.04 | 0.04 | 0.00 | 0.56 | 0.56 | 29.30 | 1.63 | 1.63 | 0.00 | 0.00 | 0.56 | 0.56 | 0.00 | 0.56 | 0.56 | 0.00 | 0.00 | 0.56 | 0.23 | 0.79 | 0.10 | 0.00 | 0.00 | -0.04 | 0.00 | 0.04 | 0.00 | 0.74 | 1.87 | 0.67 | 0.43 | 0.43 | 0.15 | 0.02 | 0.14 | 2.61 | 27.42 | 30.04 | 30.04 |
| 2022-03-31T00:00:00 | annual | 0.00 | 0.00 | 1.49 | 0.00 | 0.00 | 0.70 | 0.44 | 19.46 | 1.49 | 1.05 | -0.02 | 0.04 | 0.02 | 0.70 | 0.70 | 21.48 | 1.63 | 1.63 | 0.00 | 0.00 | 0.70 | 0.70 | 0.00 | 0.70 | 0.70 | 0.00 | 0.00 | 0.70 | 0.32 | 1.01 | 0.13 | 0.00 | 0.00 | -0.02 | 0.00 | 0.04 | 0.02 | 0.91 | 2.02 | 0.58 | 0.43 | 0.43 | 0.20 | 0.01 | 0.19 | 2.92 | 19.46 | 22.38 | 22.38 |
| 2021-03-31T00:00:00 | annual | 0.10 | 0.00 | 2.12 | 0.28 | 0.28 | 1.24 | 0.41 | 32.43 | 2.40 | 1.98 | -0.05 | 0.06 | 0.02 | 1.06 | 1.24 | 34.56 | 1.63 | 1.63 | 0.00 | 0.00 | 1.24 | 1.24 | 0.00 | 1.24 | 1.24 | 0.00 | 0.00 | 1.24 | 0.68 | 1.92 | 0.50 | 0.28 | -0.28 | -0.05 | 0.00 | 0.06 | 0.02 | 1.19 | 2.14 | 0.63 | 0.41 | 0.41 | 0.19 | 0.01 | 0.18 | 3.32 | 32.43 | 35.75 | 35.75 |
FII & DII Data (In Cr)
| Date | FII Gross Purchase | FII Gross Sales | FII Net Purchase / Sales | DII Gross Purchase | DII Gross Sales | DII Net Purchase / Sales |
|---|---|---|---|---|---|---|
| 2025-02-03 | 12,505.92 | 16,464.29 | -3,958.37 | 19,319.48 | 16,611.25 | 2,708.23 |
| 2025-01-30 | 10,513.63 | 15,096.58 | -4,582.95 | 13,934.35 | 11,768.46 | 2,165.89 |
| 2025-01-29 | 7,644.40 | 10,230.83 | -2,586.43 | 12,871.38 | 11,078.67 | 1,792.71 |
| 2025-01-27 | 9,488.57 | 14,504.03 | -5,015.46 | 16,503.43 | 9,861.28 | 6,642.15 |
| 2025-01-24 | 11,230.47 | 13,988.96 | -2,758.49 | 12,835.41 | 10,433.10 | 2,402.31 |
| 2025-01-23 | 13,316.55 | 18,779.07 | -5,462.52 | 14,412.73 | 10,700.18 | 3,712.55 |
| 2025-01-22 | 12,936.64 | 16,962.89 | -4,026.25 | 15,437.18 | 11,796.96 | 3,640.22 |
Piotroski F-Score
5/9
0
1
2
3
4
5
6
7
8
9
Key Metrics
EPS
0.33
P/E
182.54546
P/B
5.3857846
Dividend Yield
N/A
Market Cap
98.41 Cr.
Face Value
11.185
Book Value
11.185
ROE
1.38%
EBITDA Growth
1.20 Cr.
Debt/Equity
2.411
Short Term
Subscribe to unlock this feature
Medium Term
Subscribe to unlock this feature
Long Term
Subscribe to unlock this feature
Yearly Stock Performance Heatmap
Latest Updates
Ashoka Buildcon Arm Signs Rs 1,391 Crore Pact With NHAI
Ashoka Buildcon Ltd. announced on Monday, via an exchange filing, that its wholly owned subsidiary, Ashoka Bowaichandi Guskara Road Pvt Ltd., has exec...
Budget 2025: Rahul Bajoria On Addressing Income Growth And Consumption Trends
"However, discretionary, high-value consumption is taking a step back due to income growth settling at high single digits." Over the past fe...
FPIs Stay Net Sellers, Sell Stocks Worth Rs 2,575 Crore
Foreign portfolio investors stayed net sellers for the second straight session on Monday and sold stocks worth approximately Rs 2,575.1 crore, accordi...
Budget 2025: AMFI Seeks Tax Policy Reforms To Drive Mutual Fund Investments In 15-Point Proposal
The Association of Mutual Funds of India on Monday released a 15-point proposal for Union Budget 2025-26 requesting changes in tax policies that are i...
Apple iPhone SE 4: Price To Features, 11 Things You Need To Know
iPhone 16e (Not iPhone SE 4): If recent reports are to be believed, Apple may discontinue the SE label and rename iPhone SE 4 as iPhone 16e. Most Affo...
Rupee Closed Weaker Against The US Dollar
The rupee weakened by five paise to close at 85.83 against the US dollar. The Indian rupee had declined to a fresh low against the US dollar during th...
Table Space Founder Amit Banerji Dies Of Heart Attack At Age Of 45
Amit Banerji, the founder, chairman and chief executive officer of managed workspace provider Table Space, died after suffering from a heart attack, r...
War Fatigue, Economic Breakdown Or Pro-West? Why Syria's Al-Sharaa Is Seen Soft On Israel
The strategic positions have been used by Israeli forces to carry out hundreds of strikes to destroy Syria's military infrastructure. In 2011, be...
Popular Questions
What is the Market Cap of biofilchem?
The market capitalization of Biofil Chemicals and Pharmaceuticals Limited is ₹98 Cr as of 05 Feb 2025.
What are the PE and PB ratios of Biofil Chemicals and Pharmaceuticals Limited?
The PE and PB ratios of Biofil Chemicals and Pharmaceuticals Limited are Not Available and 5.3857846 respectively as of 05 Feb 2025.
What is the 52 Week High of Biofil Chemicals and Pharmaceuticals Limited?
The 52-week high of Biofil Chemicals and Pharmaceuticals Limited is ₹91.87 as of 05 Feb 2025.
What is the 52 Week Low of Biofil Chemicals and Pharmaceuticals Limited?
The 52-week low of Biofil Chemicals and Pharmaceuticals Limited is ₹53.45 as of 05 Feb 2025.
What are the earnings per share (EPS) for Biofil Chemicals and Pharmaceuticals Limited?
The Earnings Per Share (EPS) of Biofil Chemicals and Pharmaceuticals Limited is ₹0.33 as per the most recent quarterly results available on Fincept.
What is the ROE (Return on Equity) of Biofil Chemicals and Pharmaceuticals Limited?
The Return on Equity (ROE) of Biofil Chemicals and Pharmaceuticals Limited is 1.38% as per the most recent financial year data. Explore more on Fincept.